{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,8]],"date-time":"2026-07-08T11:32:52Z","timestamp":1783510372454,"version":"3.55.0"},"reference-count":181,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2020,11,20]],"date-time":"2020-11-20T00:00:00Z","timestamp":1605830400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Med."],"abstract":"<jats:p>Focal segmental glomerulosclerosis (FSGS) is a histological term that describes a pathologic renal entity affecting both adults and children, with a wide array of possible underlying etiologies. Podocyte damage with scarring, the hallmark of this condition, leads to altered permeability of the glomerular barrier, which may result in massive proteinuria and relentless renal function deterioration. A definite cause of focal segmental glomerulosclerosis can be confirmed in a minority of cases, while most forms have been traditionally labeled as primary or idiopathic. Despite this definition, increasing evidence indicates that primary forms are a heterogenous group rather than a single disease entity: several circulating factors that may affect glomerular permeability have been proposed as potential culprits, and both humoral and cellular immunity have been implicated in the pathogenesis of the disease. Consistently, immunosuppressive drugs are considered as the cornerstone of treatment for primary focal segmental glomerulosclerosis, but response to these agents and long-term outcomes are highly variable. In this review we provide a summary of historical and recent advances on the pathogenesis of primary focal segmental glomerulosclerosis, focusing on implications for its differential diagnosis and treatment.<\/jats:p>","DOI":"10.3389\/fmed.2020.604961","type":"journal-article","created":{"date-parts":[[2020,11,20]],"date-time":"2020-11-20T06:30:38Z","timestamp":1605853838000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":19,"title":["Autoimmunity in Focal Segmental Glomerulosclerosis: A Long-Standing Yet Elusive Association"],"prefix":"10.3389","volume":"7","author":[{"given":"Manuel Alfredo","family":"Podest\u00e0","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Claudio","family":"Ponticelli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2020,11,20]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"81","DOI":"10.2215\/CJN.02560315","article-title":"Complete remission in the nephrotic syndrome study network","volume":"11","author":"Gipson","year":"2016","journal-title":"Clin J Am Soc Nephrol."},{"key":"B2","doi-asserted-by":"publisher","first-page":"2398","DOI":"10.1056\/NEJMra1106556","article-title":"Focal segmental glomerulosclerosis","volume":"365","author":"D'Agati","year":"2011","journal-title":"N Engl J Med."},{"key":"B3","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s41572-020-0196-7","article-title":"Podocytopathies","volume":"6","author":"Kopp","year":"2020","journal-title":"Nat Rev Dis Primers."},{"key":"B4","doi-asserted-by":"publisher","first-page":"3005","DOI":"10.1097\/01.ASN.0000039661.06947.FD","article-title":"Podocyte biology and response to injury","volume":"13","author":"Mundel","year":"2002","journal-title":"J Am Soc Nephrol."},{"key":"B5","doi-asserted-by":"publisher","first-page":"248","DOI":"10.1016\/j.stemcr.2015.07.003","article-title":"Podocyte regeneration driven by renal progenitors determines glomerular disease remission and can be pharmacologically enhanced","volume":"5","author":"Lasagni","year":"2015","journal-title":"Stem Cell Rep."},{"key":"B6","doi-asserted-by":"publisher","first-page":"1221","DOI":"10.1016\/j.kint.2016.01.012","article-title":"Podocyte injury and its consequences","volume":"89","author":"Nagata","year":"2016","journal-title":"Kidney Int."},{"key":"B7","doi-asserted-by":"publisher","first-page":"759","DOI":"10.1681\/ASN.2017090958","article-title":"Differentiating primary, genetic, and secondary FSGS in adults: a clinicopathologic approach","volume":"29","author":"De Vriese","year":"2018","journal-title":"J Am Soc Nephrol."},{"key":"B8","doi-asserted-by":"publisher","first-page":"405","DOI":"10.1007\/s00467-016-3358-9","article-title":"Mechanical challenges to the glomerular filtration barrier: adaptations and pathway to sclerosis","volume":"32","author":"Kriz","year":"2017","journal-title":"Pediatr Nephrol."},{"key":"B9","doi-asserted-by":"publisher","first-page":"502","DOI":"10.2215\/CJN.05960616","article-title":"Focal segmental glomerulosclerosis","volume":"12","author":"Rosenberg","year":"2017","journal-title":"Clin J Am Soc Nephrol."},{"key":"B10","doi-asserted-by":"publisher","first-page":"323","DOI":"10.1146\/annurev-physiol-021119-034345","article-title":"APOL1 and kidney disease: from genetics to biology","volume":"82","author":"Friedman","year":"2020","journal-title":"Annu Rev Physiol."},{"key":"B11","doi-asserted-by":"publisher","first-page":"6967378","DOI":"10.1155\/2016\/6967378","article-title":"Interferon induced focal segmental glomerulosclerosis","volume":"2016","author":"Kayar","year":"2016","journal-title":"Case Rep Nephrol."},{"key":"B12","doi-asserted-by":"publisher","first-page":"1385","DOI":"10.1038\/ki.2008.356","article-title":"Bisphosphonate nephrotoxicity","volume":"74","author":"Perazella","year":"2008","journal-title":"Kidney Int."},{"key":"B13","doi-asserted-by":"publisher","first-page":"535","DOI":"10.1186\/s12885-015-1536-y","article-title":"Collapsing focal segmental glomerulosclerosis following long-term treatment with oral ibandronate: case report and review of literature","volume":"15","author":"Jia","year":"2015","journal-title":"BMC Cancer."},{"key":"B14","doi-asserted-by":"publisher","first-page":"655","DOI":"10.2215\/CJN.00300106","article-title":"Chronic nephropathies of cocaine and heroin abuse: a critical review","volume":"1","author":"Jaffe","year":"2006","journal-title":"Clin J Am Soc Nephrol."},{"key":"B15","first-page":"536","article-title":"Cyclosporine nephropathy: pathophysiology and clinical impact","volume":"16","author":"Shihab","year":"1996","journal-title":"Semin Nephrol."},{"key":"B16","doi-asserted-by":"publisher","first-page":"F1168","DOI":"10.1152\/ajprenal.00145.2016","article-title":"What we need to know about the effect of lithium on the kidney","volume":"311","author":"Gong","year":"2016","journal-title":"Am J Physiol Renal Physiol."},{"key":"B17","doi-asserted-by":"publisher","first-page":"513","DOI":"10.1016\/j.semnephrol.2008.08.005","article-title":"HIV-Associated nephropathy: clinical presentation, pathology, and epidemiology in the era of antiretroviral therapy","volume":"28","author":"Wyatt","year":"2008","journal-title":"Semin Nephrol."},{"key":"B18","doi-asserted-by":"publisher","first-page":"759","DOI":"10.1016\/j.ekir.2020.04.030","article-title":"COVID-19\u2013associated collapsing glomerulopathy: an emerging entity","volume":"5","author":"Nasr","year":"2020","journal-title":"Kidney Int Rep."},{"key":"B19","doi-asserted-by":"publisher","first-page":"2126","DOI":"10.1046\/j.1523-1755.2001.00727.x","article-title":"Association of parvovirus B19 infection with idiopathic collapsing glomerulopathy","volume":"59","author":"Moudgil","year":"2001","journal-title":"Kidney Int."},{"key":"B20","doi-asserted-by":"publisher","first-page":"7351964","DOI":"10.1155\/2016\/7351964","article-title":"Infection-related focal segmental glomerulosclerosis in children","volume":"2016","author":"Dettmar","year":"2016","journal-title":"Biomed Res Int."},{"key":"B21","doi-asserted-by":"publisher","first-page":"343","DOI":"10.1016\/S0140-6736(72)91734-5","article-title":"Recurrence of idiopathic nephrotic syndrome after renal transplantation","volume":"2","author":"Hoyer","year":"1972","journal-title":"Lancet."},{"key":"B22","doi-asserted-by":"publisher","first-page":"540","DOI":"10.1097\/00007890-198810000-00014","article-title":"Plasma exchange for recurrent nephrotic syndrome following renal transplantation","volume":"46","author":"Laufer","year":"1988","journal-title":"Transplantation."},{"key":"B23","doi-asserted-by":"publisher","first-page":"247","DOI":"10.2215\/CJN.08970719","article-title":"Recurrence of FSGS after kidney transplantation in adults","volume":"15","author":"Uffing","year":"2020","journal-title":"Clin J Am Soc Nephrol."},{"key":"B24","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1056\/NEJM199401063300102","article-title":"Effect of plasma protein adsorption on protein excretion in kidney-transplant recipients with recurrent nephrotic syndrome","volume":"330","author":"Dantal","year":"1994","journal-title":"N Engl J Med."},{"key":"B25","doi-asserted-by":"publisher","first-page":"1648","DOI":"10.1056\/NEJMc1202500","article-title":"Resolution of recurrent focal segmental glomerulosclerosis after retransplantation","volume":"366","author":"Gallon","year":"2012","journal-title":"N Engl J Med."},{"key":"B26","doi-asserted-by":"publisher","first-page":"878","DOI":"10.1056\/NEJM199604043341402","article-title":"Circulating factor associated with increased glomerular permeability to albumin in recurrent focal segmental glomerulosclerosis","volume":"334","author":"Savin","year":"1996","journal-title":"N Engl J Med."},{"key":"B27","first-page":"32","article-title":"Increased urinary protein excretion in the rat produced by serum from a patient with recurrent focal glomerular sclerosis after renal transplantation","volume":"22","author":"Zimmerman","year":"1984","journal-title":"Clin Nephrol."},{"key":"B28","doi-asserted-by":"publisher","first-page":"386","DOI":"10.1056\/NEJM200102013440517","article-title":"Transmission of glomerular permeability factor from a mother to her child","volume":"344","author":"Kemper","year":"2001","journal-title":"N Engl J Med."},{"key":"B29","doi-asserted-by":"publisher","first-page":"556","DOI":"10.1016\/S0140-6736(74)91880-7","article-title":"Pathogenesis of lipoid nephrosis: a disorder of T-cell function","volume":"2","author":"Shalhoub","year":"1974","journal-title":"Lancet."},{"key":"B30","doi-asserted-by":"publisher","first-page":"453","DOI":"10.1038\/ki.1991.232","article-title":"A glomerular permeability factor produced by human T cell hybridomas","volume":"40","author":"Koyama","year":"1991","journal-title":"Kidney Int."},{"key":"B31","doi-asserted-by":"publisher","first-page":"370","DOI":"10.1159\/000185325","article-title":"Studies of a glomerular permeability factor in patients with minimal-change nephrotic syndrome","volume":"51","author":"Yoshizawa","year":"1989","journal-title":"Nephron."},{"key":"B32","doi-asserted-by":"publisher","first-page":"2207","DOI":"10.1093\/ndt\/gfu355","article-title":"Permeability factors in idiopathic nephrotic syndrome: historical perspectives and lessons for the future","volume":"29","author":"Maas","year":"2014","journal-title":"Nephrol Dial Transplant."},{"key":"B33","doi-asserted-by":"crossref","first-page":"552","DOI":"10.1681\/ASN.V103552","article-title":"\u201cThe FSGS factor:\u201d enrichment and in vivo effect of activity from focal segmental glomerulosclerosis plasma","volume":"10","author":"Sharma","year":"1999","journal-title":"J Am Soc Nephrol."},{"key":"B34","doi-asserted-by":"publisher","first-page":"2115","DOI":"10.2215\/CJN.03800609","article-title":"Circulating permeability factors in idiopathic nephrotic syndrome and focal segmental glomerulosclerosis","volume":"5","author":"McCarthy","year":"2010","journal-title":"Clin J Am Soc Nephrol."},{"key":"B35","doi-asserted-by":"publisher","first-page":"714964","DOI":"10.1155\/2015\/714964","article-title":"Renal and hematological effects of CLCF-1, a B-cell-stimulating cytokine of the IL-6 family","volume":"2015","author":"Savin","year":"2015","journal-title":"J Immunol Res."},{"key":"B36","doi-asserted-by":"publisher","first-page":"288","DOI":"10.1016\/j.trsl.2008.04.001","article-title":"Galactose binds to focal segmental glomerulosclerosis permeability factor and inhibits its activity","volume":"151","author":"Savin","year":"2008","journal-title":"Transl Res."},{"key":"B37","doi-asserted-by":"publisher","first-page":"205","DOI":"10.1016\/j.krcp.2012.10.002","article-title":"Permeability factors in nephrotic syndrome and focal segmental glomerulosclerosis","volume":"31","author":"Savin","year":"2012","journal-title":"Kidney Res Clin Pract."},{"key":"B38","doi-asserted-by":"publisher","first-page":"3765608","DOI":"10.1155\/2016\/3765608","article-title":"Circulating permeability factors in primary focal segmental glomerulosclerosis: a review of proposed candidates","volume":"2016","author":"K\u00f6nigshausen","year":"2016","journal-title":"Biomed Res Int."},{"key":"B39","doi-asserted-by":"publisher","first-page":"952","DOI":"10.1038\/nm.2411","article-title":"Circulating urokinase receptor as a cause of focal segmental glomerulosclerosis","volume":"17","author":"Wei","year":"2011","journal-title":"Nat Med."},{"key":"B40","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1038\/nm1696","article-title":"Modification of kidney barrier function by the urokinase receptor","volume":"14","author":"Wei","year":"2008","journal-title":"Nat Med."},{"key":"B41","doi-asserted-by":"publisher","first-page":"4755","DOI":"10.1128\/MCB.00730-13","article-title":"Rac1 activation in podocytes induces rapid foot process effacement and proteinuria","volume":"33","author":"Yu","year":"2013","journal-title":"Mol Cell Biol."},{"key":"B42","doi-asserted-by":"publisher","first-page":"649","DOI":"10.1097\/TP.0b013e31829eda4f","article-title":"Podocyte effacement closely links to suPAR levels at time of post-transplant focal segmental glomerulosclerosis occurrence and improves with therapy","volume":"96","author":"Alachkar","year":"2013","journal-title":"Transplantation."},{"key":"B43","doi-asserted-by":"publisher","first-page":"2051","DOI":"10.1681\/ASN.2012030302","article-title":"Circulating suPAR in two cohorts of primary FSGS","volume":"23","author":"Wei","year":"2012","journal-title":"J Am Soc Nephrol."},{"key":"B44","doi-asserted-by":"publisher","first-page":"1043","DOI":"10.1038\/ki.2012.32","article-title":"Serum-soluble urokinase receptor concentration in primary FSGS","volume":"81","author":"Maas","year":"2012","journal-title":"Kidney Int."},{"key":"B45","doi-asserted-by":"publisher","first-page":"1304","DOI":"10.2215\/CJN.07680712","article-title":"Serum soluble urokinase-type plasminogen activator receptor levels and idiopathic FSGS in children: a single-center report","volume":"8","author":"Bock","year":"2013","journal-title":"Clin J Am Soc Nephrol."},{"key":"B46","doi-asserted-by":"publisher","first-page":"636","DOI":"10.1038\/ki.2013.505","article-title":"The soluble urokinase receptor is not a clinical marker for focal segmental glomerulosclerosis","volume":"85","author":"Meijers","year":"2014","journal-title":"Kidney Int."},{"key":"B47","doi-asserted-by":"publisher","first-page":"641","DOI":"10.1038\/ki.2013.544","article-title":"A multicenter cross-sectional study of circulating soluble urokinase receptor in Japanese patients with glomerular disease","volume":"85","author":"Wada","year":"2014","journal-title":"Kidney Int."},{"key":"B48","doi-asserted-by":"publisher","first-page":"649","DOI":"10.1038\/ki.2013.546","article-title":"Serum-soluble urokinase receptor levels do not distinguish focal segmental glomerulosclerosis from other causes of nephrotic syndrome in children","volume":"85","author":"Sinha","year":"2014","journal-title":"Kidney Int."},{"key":"B49","doi-asserted-by":"publisher","first-page":"564","DOI":"10.1038\/ki.2014.346","article-title":"A reassessment of soluble urokinase-type plasminogen activator receptor in glomerular disease","volume":"87","author":"Spinale","year":"2015","journal-title":"Kidney Int."},{"key":"B50","doi-asserted-by":"publisher","first-page":"1662","DOI":"10.1681\/ASN.2013040425","article-title":"Administration of recombinant soluble urokinase receptor per se is not sufficient to induce podocyte alterations and proteinuria in mice","volume":"25","author":"Cathelin","year":"2014","journal-title":"J Am Soc Nephrol."},{"key":"B51","doi-asserted-by":"publisher","first-page":"54","DOI":"10.1097\/TP.0000000000002930","article-title":"Further evidence that the soluble urokinase plasminogen activator receptor does not directly injure mice or human podocytes","volume":"104","author":"Harel","year":"2020","journal-title":"Transplantation."},{"key":"B52","doi-asserted-by":"publisher","first-page":"1611","DOI":"10.1681\/ASN.2014030257","article-title":"Soluble urokinase-Type plasminogen activator receptor in FSGS: stirred but not shaken","volume":"25","author":"Reiser","year":"2014","journal-title":"J Am Soc Nephrol."},{"key":"B53","doi-asserted-by":"publisher","first-page":"13783","DOI":"10.1038\/s41598-019-50405-8","article-title":"Diagnostic and prognostic value of soluble urokinase-type plasminogen activator receptor (supar) in focal segmental glomerulosclerosis and impact of detection method","volume":"9","author":"Winnicki","year":"2019","journal-title":"Sci Rep."},{"key":"B54","doi-asserted-by":"publisher","first-page":"491","DOI":"10.1111\/j.1365-2249.2005.02862.x","article-title":"Circulating anti-actin and anti-ATP synthase antibodies identify a sub-set of patients with idiopathic nephrotic syndrome","volume":"141","author":"Musante","year":"2005","journal-title":"Clin Exp Immunol."},{"key":"B55","doi-asserted-by":"publisher","first-page":"971","DOI":"10.1056\/NEJMc1207233","article-title":"Angiotensin antibodies and focal segmental glomerulosclerosis","volume":"368","author":"Alachkar","year":"2013","journal-title":"N Engl J Med."},{"key":"B56","doi-asserted-by":"publisher","first-page":"256ra136","DOI":"10.1126\/scitranslmed.3008538","article-title":"A circulating antibody panel for pretransplant prediction of FSGS recurrence after kidney transplantation","volume":"6","author":"Delville","year":"2014","journal-title":"Sci Transl Med."},{"key":"B57","doi-asserted-by":"publisher","first-page":"300","DOI":"10.3978\/j.issn.2305-5839.2015.11.08","article-title":"Circulating CD40 autoantibody and suPAR synergy drives glomerular injury","volume":"3","author":"Wei","year":"2015","journal-title":"Ann Transl Med."},{"key":"B58","first-page":"581","article-title":"Evaluation of T lymphocyte subpopulations in children with nephrotic syndrome","volume":"52","author":"Herrod","year":"1983","journal-title":"Clin Exp Immunol."},{"key":"B59","doi-asserted-by":"publisher","first-page":"1251","DOI":"10.1007\/s00467-008-0793-2","article-title":"Stem cell mobilization in idiopathic steroid-sensitive nephrotic syndrome","volume":"23","author":"Lapillonne","year":"2008","journal-title":"Pediatr Nephrol."},{"key":"B60","doi-asserted-by":"publisher","first-page":"958","DOI":"10.1053\/ajkd.2002.32769","article-title":"T-lymphocyte populations and cytokines in childhood nephrotic syndrome","volume":"39","author":"Lama","year":"2002","journal-title":"Am J Kidney Dis."},{"key":"B61","doi-asserted-by":"publisher","first-page":"132","DOI":"10.1159\/000085357","article-title":"Changes of lymphocyte populations in pediatric steroid-sensitive nephrotic syndrome are more pronounced in remission than in relapse","volume":"25","author":"Kemper","year":"2005","journal-title":"AJN."},{"key":"B62","doi-asserted-by":"publisher","first-page":"332","DOI":"10.1159\/000350161","article-title":"The role of Th17\/IL-17 in the pathogenesis of primary nephrotic syndrome in children","volume":"37","author":"Wang","year":"2013","journal-title":"Kidney Blood Press Res."},{"key":"B63","doi-asserted-by":"publisher","first-page":"1683","DOI":"10.1007\/s00467-009-1194-x","article-title":"The prevalence of Th17 cells and FOXP3 regulate T cells (Treg) in children with primary nephrotic syndrome","volume":"24","author":"Shao","year":"2009","journal-title":"Pediatr Nephrol."},{"key":"B64","doi-asserted-by":"publisher","first-page":"643","DOI":"10.1111\/ped.13255","article-title":"Regulatory T cells and CTLA-4 in idiopathic nephrotic syndrome","volume":"59","author":"Tsuji","year":"2017","journal-title":"Pediatr Int."},{"key":"B65","doi-asserted-by":"publisher","first-page":"2732","DOI":"10.1681\/ASN.2006121346","article-title":"A humanized mouse model of idiopathic nephrotic syndrome suggests a pathogenic role for immature cells","volume":"18","author":"Sellier-Leclerc","year":"2007","journal-title":"J Am Soc Nephrol."},{"key":"B66","doi-asserted-by":"publisher","first-page":"322","DOI":"10.1159\/000360908","article-title":"Rituximab treatment for relapsing minimal change disease and focal segmental glomerulosclerosis: a systematic review","volume":"39","author":"Kronbichler","year":"2014","journal-title":"Am J Nephrol."},{"key":"B67","doi-asserted-by":"publisher","first-page":"1449","DOI":"10.1007\/s00467-017-3746-9","article-title":"Rituximab in steroid-sensitive nephrotic syndrome: lessons from clinical trials","volume":"33","author":"Iijima","year":"2018","journal-title":"Pediatr Nephrol."},{"key":"B68","doi-asserted-by":"publisher","first-page":"573","DOI":"10.1007\/s00467-017-3677-5","article-title":"Immunology of idiopathic nephrotic syndrome","volume":"33","author":"Colucci","year":"2018","journal-title":"Pediatr Nephrol."},{"key":"B69","doi-asserted-by":"publisher","first-page":"1811","DOI":"10.1681\/ASN.2015050523","article-title":"B cell reconstitution after rituximab treatment in idiopathic nephrotic syndrome","volume":"27","author":"Colucci","year":"2016","journal-title":"J Am Soc Nephrol."},{"key":"B70","doi-asserted-by":"publisher","first-page":"224","DOI":"10.1093\/ckj\/sfy067","article-title":"Continuous B-cell depletion in frequently relapsing, steroid-dependent and steroid-resistant nephrotic syndrome","volume":"12","author":"Cortazar","year":"2019","journal-title":"Clin Kidney J."},{"key":"B71","doi-asserted-by":"publisher","first-page":"971","DOI":"10.1016\/j.kint.2019.04.006","article-title":"Atypical IgM on T cells predict relapse and steroid dependence in idiopathic nephrotic syndrome","volume":"96","author":"Colucci","year":"2019","journal-title":"Kidney Int."},{"key":"B72","doi-asserted-by":"publisher","first-page":"80","DOI":"10.1038\/ncprheum0983","article-title":"Anti-CD20 antibody is an efficient therapeutic tool for the selective removal of autoreactive T cells","volume":"5","author":"Datta","year":"2009","journal-title":"Nat Clin Pract Rheumatol."},{"key":"B73","doi-asserted-by":"publisher","first-page":"1390","DOI":"10.1172\/JCI20402","article-title":"Induction of B7-1 in podocytes is associated with nephrotic syndrome","volume":"113","author":"Reiser","year":"2004","journal-title":"J Clin Invest."},{"key":"B74","doi-asserted-by":"publisher","first-page":"2416","DOI":"10.1056\/NEJMoa1304572","article-title":"Abatacept in B7-1\u2013positive proteinuric kidney disease","volume":"369","author":"Yu","year":"2013","journal-title":"N Engl J Med."},{"key":"B75","doi-asserted-by":"publisher","first-page":"1261","DOI":"10.1056\/NEJMc1400502","article-title":"Abatacept in B7-1-positive proteinuric kidney disease","volume":"370","author":"Benigni","year":"2014","journal-title":"N Engl J Med."},{"key":"B76","doi-asserted-by":"publisher","first-page":"1001","DOI":"10.1053\/j.ajkd.2014.07.023","article-title":"B7-1 immunostaining in proteinuric kidney disease","volume":"64","author":"Larsen","year":"2014","journal-title":"Am J Kidney Dis."},{"key":"B77","doi-asserted-by":"publisher","first-page":"2021","DOI":"10.1016\/j.ekir.2020.08.001","article-title":"Urinary CD80 discriminates among glomerular disease types and reflects disease activity","volume":"5","author":"Guerrico","year":"2020","journal-title":"Kidney Int Rep"},{"key":"B78","doi-asserted-by":"publisher","first-page":"525","DOI":"10.1007\/s40620-016-0272-y","article-title":"Focal segmental glomerular sclerosis: do not overlook the role of immune response","volume":"29","author":"Reggiani","year":"2016","journal-title":"J Nephrol."},{"key":"B79","doi-asserted-by":"publisher","first-page":"251","DOI":"10.1016\/S0272-6386(12)80742-6","article-title":"Elevated levels of tumor necrosis factor-alpha in the nephrotic syndrome in humans","volume":"21","author":"Suranyi","year":"1993","journal-title":"Am J Kidney Dis."},{"key":"B80","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1159\/000369576","article-title":"Effects of tumor necrosis factor-\u03b1 on podocyte expression of monocyte chemoattractant protein-1 and in diabetic nephropathy","volume":"5","author":"Chung","year":"2015","journal-title":"Nephron Extra."},{"key":"B81","doi-asserted-by":"publisher","first-page":"e0216426","DOI":"10.1371\/journal.pone.0216426","article-title":"Intrinsic tumor necrosis factor-\u03b1 pathway is activated in a subset of patients with focal segmental glomerulosclerosis","volume":"14","author":"Chung","year":"2019","journal-title":"PLoS ONE."},{"key":"B82","doi-asserted-by":"publisher","first-page":"2217","DOI":"10.1007\/s00467-012-2163-3","article-title":"TNF\u03b1 pathway blockade ameliorates toxic effects of FSGS plasma on podocyte cytoskeleton and \u03b23 integrin activation","volume":"27","author":"Bitzan","year":"2012","journal-title":"Pediatr Nephrol."},{"key":"B83","doi-asserted-by":"publisher","first-page":"e0222948","DOI":"10.1371\/journal.pone.0222948","article-title":"Identification of glomerular and podocyte-specific genes and pathways activated by sera of patients with focal segmental glomerulosclerosis","volume":"14","author":"Otalora","year":"2019","journal-title":"PLoS ONE."},{"key":"B84","doi-asserted-by":"publisher","first-page":"50","DOI":"10.1053\/j.ajkd.2009.08.019","article-title":"Phase 1 trial of adalimumab in focal segmental glomerulosclerosis (FSGS): II. Report of the FONT (Novel Therapies for Resistant FSGS) study group","volume":"55","author":"Joy","year":"2010","journal-title":"Am J Kidney Dis."},{"key":"B85","doi-asserted-by":"publisher","first-page":"367","DOI":"10.1080\/14728214.2020.1803276","article-title":"Emerging drugs for treatment of focal segmental glomerulosclerosis","volume":"25","author":"Trachtman","year":"2020","journal-title":"Expert Opin Emerg Drugs."},{"key":"B86","doi-asserted-by":"publisher","DOI":"10.1101\/427880","article-title":"Redefining nephrotic syndrome in molecular terms: outcome-associated molecular clusters and patient stratification with noninvasive surrogate biomarkers","author":"Mariani","year":"2018","journal-title":"bioRxiv [Preprint]."},{"key":"B87","doi-asserted-by":"publisher","first-page":"1435","DOI":"10.3109\/0886022X.2015.1074474","article-title":"MCP1 2518 A\/G polymorphism affects progression of childhood focal segmental glomerulosclerosis","volume":"37","author":"Besbas","year":"2015","journal-title":"Ren Fail."},{"key":"B88","doi-asserted-by":"publisher","first-page":"227","DOI":"10.1093\/ndt\/gfy380","article-title":"C\u2013C chemokine receptor type 2 mediates glomerular injury and interstitial fibrosis in focal segmental glomerulosclerosis","volume":"35","author":"Wilkening","year":"2018","journal-title":"Nephrol Dial Transplant"},{"key":"B89","doi-asserted-by":"publisher","first-page":"e0192405","DOI":"10.1371\/journal.pone.0192405","article-title":"CCR2 antagonism leads to marked reduction in proteinuria and glomerular injury in murine models of focal segmental glomerulosclerosis (FSGS)","volume":"13","author":"Miao","year":"2018","journal-title":"PLoS ONE."},{"key":"B90","doi-asserted-by":"publisher","first-page":"368","DOI":"10.1053\/j.ajkd.2003.10.024","article-title":"Pathologic classification of focal segmental glomerulosclerosis: a working proposal","volume":"43","author":"D'Agati","year":"2004","journal-title":"Am J Kidney Dis."},{"key":"B91","doi-asserted-by":"publisher","first-page":"76","DOI":"10.1038\/nrneph.2014.216","article-title":"Causes and pathogenesis of focal segmental glomerulosclerosis","volume":"11","author":"Fogo","year":"2015","journal-title":"Nat Rev Nephrol."},{"key":"B92","doi-asserted-by":"publisher","first-page":"258","DOI":"10.1681\/ASN.2014030278","article-title":"A potential role for mechanical forces in the detachment of podocytes and the progression of CKD","volume":"26","author":"Kriz","year":"2015","journal-title":"J Am Soc Nephrol."},{"key":"B93","doi-asserted-by":"publisher","first-page":"1416","DOI":"10.1038\/ki.1994.185","article-title":"Collapsing glomerulopathy: a clinically and pathologically distinct variant of focal segmental glomerulosclerosis","volume":"45","author":"Detwiler","year":"1994","journal-title":"Kidney Int."},{"key":"B94","doi-asserted-by":"publisher","first-page":"393","DOI":"10.1681\/ASN.2012020187","article-title":"IgM contributes to glomerular injury in FSGS","volume":"24","author":"Strassheim","year":"2013","journal-title":"J Am Soc Nephrol."},{"key":"B95","doi-asserted-by":"publisher","first-page":"260","DOI":"10.1186\/s12882-017-0674-7","article-title":"The impact of IgM deposits on the outcome of nephrotic syndrome in children","volume":"18","author":"Juozapaite","year":"2017","journal-title":"BMC Nephrol."},{"key":"B96","doi-asserted-by":"publisher","first-page":"961","DOI":"10.1159\/000501827","article-title":"Co-Deposition of IgM and C3 may indicate unfavorable renal outcomes in adult patients with primary focal segmental glomerulosclerosis","volume":"44","author":"Mirioglu","year":"2019","journal-title":"Kidney Blood Press Res."},{"key":"B97","doi-asserted-by":"publisher","first-page":"1582","DOI":"10.2215\/CJN.01190216","article-title":"Clinical significance of IgM and C3 glomerular deposition in primary focal segmental glomerulosclerosis","volume":"11","author":"Zhang","year":"2016","journal-title":"Clin J Am Soc Nephrol."},{"key":"B98","doi-asserted-by":"publisher","first-page":"375","DOI":"10.1093\/ndt\/gfu035","article-title":"Focal segmental glomerulosclerosis: towards a better understanding for the practicing nephrologist","volume":"30","author":"Sethi","year":"2015","journal-title":"Nephrol Dial Transplant."},{"key":"B99","doi-asserted-by":"publisher","first-page":"649","DOI":"10.1007\/s00467-018-4122-0","article-title":"Infants with congenital nephrotic syndrome have comparable outcomes to infants with other renal diseases","volume":"34","author":"Dufek","year":"2019","journal-title":"Pediatr Nephrol."},{"key":"B100","doi-asserted-by":"publisher","first-page":"68","DOI":"10.1093\/ndt\/14.suppl_3.68","article-title":"Clinical picture and outcome of primary focal segmental glomerulosclerosis","volume":"14","author":"Korbet","year":"1999","journal-title":"Nephrol Dial Transplant."},{"key":"B101","doi-asserted-by":"publisher","first-page":"251","DOI":"10.1586\/eci.12.109","article-title":"Current and emerging treatments for idiopathic focal and segmental glomerulosclerosis in adults","volume":"9","author":"Ponticelli","year":"2013","journal-title":"Expert Rev Clin Immunol."},{"key":"B102","doi-asserted-by":"publisher","first-page":"1301","DOI":"10.1056\/NEJM197912133012401","article-title":"Collaborative study of the adult idiopathic nephrotic syndrome","volume":"301","year":"1979","journal-title":"N Engl J Med."},{"key":"B103","first-page":"139","article-title":"Clinical practice guidelines for glomerulonephritis","volume":"2","year":"2012","journal-title":"Kidney Int."},{"key":"B104","doi-asserted-by":"publisher","first-page":"72","DOI":"10.1053\/ajkd.1998.v32.pm9669427","article-title":"Long-term outcome in children and adults with classic focal segmental glomerulosclerosis","volume":"32","author":"Cattran","year":"1998","journal-title":"Am J Kidney Dis."},{"key":"B105","doi-asserted-by":"publisher","first-page":"344","DOI":"10.1007\/s00467-005-2097-0","article-title":"Differential risk of remission and ESRD in childhood FSGS","volume":"21","author":"Gipson","year":"2006","journal-title":"Pediatr Nephrol."},{"key":"B106","doi-asserted-by":"publisher","first-page":"414","DOI":"10.2215\/CJN.04780517","article-title":"An outcomes-based definition of proteinuria remission in focal segmental glomerulosclerosis","volume":"13","author":"Troost","year":"2018","journal-title":"Clin J Am Soc Nephrol."},{"key":"B107","doi-asserted-by":"publisher","first-page":"618","DOI":"10.1016\/S0272-6386(99)70384-7","article-title":"Can prolonged treatment improve the prognosis in adults with focal segmental glomerulosclerosis?","volume":"34","author":"Ponticelli","year":"1999","journal-title":"Am J Kidney Dis."},{"key":"B108","doi-asserted-by":"publisher","first-page":"1061","DOI":"10.1681\/ASN.2004070593","article-title":"Focal and segmental glomerulosclerosis: definition and relevance of a partial remission","volume":"16","author":"Troyanov","year":"2005","journal-title":"J Am Soc Nephrol."},{"key":"B109","doi-asserted-by":"publisher","first-page":"81","DOI":"10.1159\/000442999","article-title":"Primary FSGS in nephrotic adults: clinical profile, response to immunosuppression and outcome","volume":"132","author":"Bagchi","year":"2016","journal-title":"NEF."},{"key":"B110","doi-asserted-by":"publisher","first-page":"1392","DOI":"10.1038\/ki.2015.241","article-title":"Identifying the ideal metric of proteinuria as a predictor of renal outcome in idiopathic glomerulonephritis","volume":"88","author":"Barbour","year":"2015","journal-title":"Kidney Int."},{"key":"B111","doi-asserted-by":"publisher","first-page":"v28","DOI":"10.1093\/ndt\/gfg1040","article-title":"The role of arterial hypertension in the progression of non-diabetic glomerular diseases","volume":"18","author":"Ljuti\u0107","year":"2003","journal-title":"Nephrol Dial Transplant."},{"key":"B112","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s00795-016-0146-3","article-title":"A mechanistic link between renal ischemia and fibrosis","volume":"50","author":"Tanaka","year":"2017","journal-title":"Med Mol Morphol."},{"key":"B113","doi-asserted-by":"publisher","first-page":"399","DOI":"10.2215\/CJN.06100612","article-title":"Association of histologic variants in FSGS clinical trial with presenting features and outcomes","volume":"8","author":"D'Agati","year":"2013","journal-title":"CJASN."},{"key":"B114","doi-asserted-by":"publisher","first-page":"310","DOI":"10.1093\/ndt\/gfw443","article-title":"Interstitial fibrosis scored on whole-slide digital imaging of kidney biopsies is a predictor of outcome in proteinuric glomerulopathies","volume":"33","author":"Mariani","year":"2018","journal-title":"Nephrol Dial Transplant."},{"key":"B115","doi-asserted-by":"publisher","first-page":"52","DOI":"10.1186\/1471-2369-15-52","article-title":"Clinical features and outcomes of focal segmental glomerulosclerosis pathologic variants in Korean adult patients","volume":"15","author":"Kwon","year":"2014","journal-title":"BMC Nephrol."},{"key":"B116","doi-asserted-by":"publisher","first-page":"1752","DOI":"10.2215\/CJN.13091215","article-title":"Renal survival in patients with collapsing compared with not otherwise specified FSGS","volume":"11","author":"Laurin","year":"2016","journal-title":"Clin J Am Soc Nephrol."},{"key":"B117","doi-asserted-by":"publisher","first-page":"1219","DOI":"10.1093\/ndt\/gfy374","article-title":"Utility of Columbia classification in focal segmental glomerulosclerosis: renal prognosis and treatment response among the pathological variants","volume":"35","author":"Tsuchimoto","year":"2020","journal-title":"Nephrol Dial Transplant."},{"key":"B118","doi-asserted-by":"publisher","first-page":"2041","DOI":"10.2215\/CJN.03060316","article-title":"Long-term outcome of kidney transplantation in recipients with focal segmental glomerulosclerosis","volume":"11","author":"Francis","year":"2016","journal-title":"Clin J Am Soc Nephrol."},{"key":"B119","doi-asserted-by":"publisher","first-page":"e13385","DOI":"10.1111\/petr.13385","article-title":"European society of pediatric nephrology survey on current practice regarding recurrent focal segmental glomerulosclerosis after pediatric kidney transplantation","volume":"23","author":"Bouts","year":"2019","journal-title":"Pediatr Transplant."},{"key":"B120","doi-asserted-by":"publisher","first-page":"89","DOI":"10.2215\/CJN.06060519","article-title":"Reverse phenotyping after whole-exome sequencing in steroid-resistant nephrotic syndrome","volume":"15","author":"Landini","year":"2020","journal-title":"Clin J Am Soc Nephrol."},{"key":"B121","doi-asserted-by":"publisher","first-page":"1279","DOI":"10.1681\/ASN.2014050489","article-title":"A single-gene cause in 29.5% of cases of steroid-resistant nephrotic syndrome","volume":"26","author":"Sadowski","year":"2015","journal-title":"J Am Soc Nephrol."},{"key":"B122","doi-asserted-by":"publisher","first-page":"1013","DOI":"10.1016\/j.kint.2018.07.024","article-title":"Identification of genetic causes for sporadic steroid-resistant nephrotic syndrome in adults","volume":"94","author":"Gribouval","year":"2018","journal-title":"Kidney Int."},{"key":"B123","doi-asserted-by":"publisher","first-page":"2309","DOI":"10.1007\/s00467-014-2781-z","article-title":"Congenital nephrotic syndrome and recurrence of proteinuria after renal transplantation","volume":"29","author":"Holmberg","year":"2014","journal-title":"Pediatr Nephrol."},{"key":"B124","doi-asserted-by":"publisher","first-page":"1038","DOI":"10.1038\/sj.ki.5001655","article-title":"Direct effects of dexamethasone on human podocytes","volume":"70","author":"Xing","year":"2006","journal-title":"Kidney Int."},{"key":"B125","doi-asserted-by":"publisher","first-page":"2473","DOI":"10.1111\/j.1523-1755.2005.00723.x","article-title":"Glucocorticoids protect and enhance recovery of cultured murine podocytes via actin filament stabilization","volume":"68","author":"Ransom","year":"2005","journal-title":"Kidney Int."},{"key":"B126","doi-asserted-by":"publisher","first-page":"1043","DOI":"10.1007\/s00467-015-3106-6","article-title":"Corticosteroids for the initial episode of steroid-sensitive nephrotic syndrome","volume":"30","author":"Hodson","year":"2015","journal-title":"Pediatr Nephrol."},{"key":"B127","doi-asserted-by":"publisher","first-page":"938","DOI":"10.1016\/0002-9343(87)90155-0","article-title":"Evidence suggesting under-treatment in adults with idiopathic focal segmental glomerulosclerosis. Regional glomerulonephritis registry study","volume":"82","author":"Pei","year":"1987","journal-title":"Am J Med."},{"key":"B128","doi-asserted-by":"publisher","first-page":"168","DOI":"10.1159\/000187177","article-title":"Idiopathic adult focal segmental glomerulosclerosis: a clinicopathological study and response to steroid","volume":"63","author":"Agarwal","year":"1993","journal-title":"Nephron."},{"key":"B129","doi-asserted-by":"publisher","first-page":"2169","DOI":"10.1097\/01.ASN.0000135051.62500.97","article-title":"Focal segmental glomerulosclerosis in nephrotic adults: presentation, prognosis, and response to therapy of the histologic variants","volume":"15","author":"Chun","year":"2004","journal-title":"JASN."},{"key":"B130","doi-asserted-by":"publisher","first-page":"1769","DOI":"10.1681\/ASN.2012040389","article-title":"Treatment of primary FSGS in adults","volume":"23","author":"Korbet","year":"2012","journal-title":"JASN."},{"key":"B131","doi-asserted-by":"publisher","first-page":"815","DOI":"10.2215\/CJN.12991117","article-title":"Glucocorticoids in the treatment of glomerular diseases: pitfalls and pearls","volume":"13","author":"Ponticelli","year":"2018","journal-title":"Clin J Am Soc Nephrol."},{"key":"B132","doi-asserted-by":"publisher","first-page":"851","DOI":"10.1007\/s40620-019-00602-5","article-title":"Prevention of complications from use of conventional immunosuppressants: a critical review","volume":"32","author":"Ponticelli","year":"2019","journal-title":"J Nephrol."},{"key":"B133","doi-asserted-by":"publisher","first-page":"931","DOI":"10.1038\/nm.1857","article-title":"The actin cytoskeleton of kidney podocytes is a direct target of the antiproteinuric effect of cyclosporine A","volume":"14","author":"Faul","year":"2008","journal-title":"Nat Med."},{"key":"B134","doi-asserted-by":"publisher","first-page":"32087","DOI":"10.1038\/srep32087","article-title":"Calcineurin inhibitors cyclosporin A and tacrolimus protect against podocyte injury induced by puromycin aminonucleoside in rodent models","volume":"6","author":"Shen","year":"2016","journal-title":"Sci Rep."},{"key":"B135","doi-asserted-by":"publisher","first-page":"1377","DOI":"10.1038\/ki.1993.194","article-title":"A randomized trial of cyclosporine in steroid-resistant idiopathic nephrotic syndrome","volume":"43","author":"Ponticelli","year":"1993","journal-title":"Kidney Int."},{"key":"B136","doi-asserted-by":"publisher","first-page":"2220","DOI":"10.1046\/j.1523-1755.1999.00778.x","article-title":"A randomized trial of cyclosporine in patients with steroid-resistant focal segmental glomerulosclerosis. North America nephrotic syndrome study group","volume":"56","author":"Cattran","year":"1999","journal-title":"Kidney Int."},{"key":"B137","doi-asserted-by":"publisher","first-page":"1411","DOI":"10.1016\/j.clinthera.2004.09.012","article-title":"Cyclosporine in patients with steroid-resistant nephrotic syndrome: an open-label, nonrandomized, retrospective study","volume":"26","author":"Ghiggeri","year":"2004","journal-title":"Clin Ther."},{"key":"B138","doi-asserted-by":"publisher","first-page":"2177","DOI":"10.1007\/s00467-009-1264-0","article-title":"Cyclosporine and steroid therapy in children with steroid-resistant nephrotic syndrome","volume":"24","author":"Hamasaki","year":"2009","journal-title":"Pediatr Nephrol."},{"key":"B139","doi-asserted-by":"publisher","first-page":"1477","DOI":"10.1007\/s00467-015-3109-3","article-title":"Response to cyclosporine in steroid-resistant nephrotic syndrome: discontinuation is possible","volume":"30","author":"Klaassen","year":"2015","journal-title":"Pediatr Nephrol."},{"key":"B140","doi-asserted-by":"publisher","first-page":"3055","DOI":"10.1681\/ASN.2016101121","article-title":"Long-term outcome of steroid-resistant nephrotic syndrome in children","volume":"28","author":"Trautmann","year":"2017","journal-title":"J Am Soc Nephrol."},{"key":"B141","doi-asserted-by":"publisher","first-page":"281","DOI":"10.1007\/s00467-003-1370-3","article-title":"Tacrolimus therapy in pediatric patients with treatment-resistant nephrotic syndrome","volume":"19","author":"Loeffler","year":"2004","journal-title":"Pediatr Nephrol."},{"key":"B142","doi-asserted-by":"publisher","first-page":"3062","DOI":"10.1093\/ndt\/gfh536","article-title":"Treatment of focal and segmental glomerulosclerosis in adults with tacrolimus monotherapy","volume":"19","author":"Duncan","year":"2004","journal-title":"Nephrol Dial Transplant."},{"key":"B143","doi-asserted-by":"publisher","first-page":"544","DOI":"10.1159\/000097864","article-title":"Management of steroid-resistant focal segmental glomerulosclerosis in children using tacrolimus","volume":"26","author":"Bhimma","year":"2006","journal-title":"AJN."},{"key":"B144","doi-asserted-by":"publisher","first-page":"910","DOI":"10.1093\/ndt\/gfm688","article-title":"Tacrolimus: a new therapy for steroid-resistant nephrotic syndrome in children","volume":"23","author":"Gulati","year":"2008","journal-title":"Nephrol Dial Transplant."},{"key":"B145","first-page":"1326","article-title":"Cyclosporin versus cyclophosphamide for patients with steroid-dependent and frequently relapsing idiopathic nephrotic syndrome: a multicentre randomized controlled trial","volume":"8","author":"Ponticelli","year":"1993","journal-title":"Nephrol Dial Transplant."},{"key":"B146","first-page":"53","article-title":"The impact of prolonged immunosuppression on the outcome of idiopathic focal-segmental glomerulosclerosis with nephrotic syndrome in adults. A collaborative retrospective study","volume":"36","author":"Banfi","year":"1991","journal-title":"Clin Nephrol."},{"key":"B147","doi-asserted-by":"publisher","first-page":"48","DOI":"10.4103\/0971-4065.53321","article-title":"Ponticelli regimen in idiopathic nephrotic syndrome","volume":"19","author":"Das","year":"2009","journal-title":"Indian J Nephrol."},{"key":"B148","doi-asserted-by":"publisher","first-page":"941831","DOI":"10.1155\/2013\/941831","article-title":"Urinary IgG and \u03b12-Macroglobulin are powerful predictors of outcome and responsiveness to steroids and cyclophosphamide in idiopathic focal segmental glomerulosclerosis with nephrotic syndrome","volume":"2013","author":"Bazzi","year":"2013","journal-title":"Biomed Res Int."},{"key":"B149","doi-asserted-by":"publisher","first-page":"271","DOI":"10.1007\/s004670000523","article-title":"A meta-analysis of cytotoxic treatment for frequently relapsing nephrotic syndrome in children","volume":"16","author":"Latta","year":"2001","journal-title":"Pediatr Nephrol."},{"key":"B150","doi-asserted-by":"publisher","first-page":"590","DOI":"10.1007\/s004670050167","article-title":"Cyclophosphamide does not benefit patients with focal segmental glomerulosclerosis","volume":"10","author":"Tarshish","year":"1996","journal-title":"Pediatr Nephrol."},{"key":"B151","doi-asserted-by":"publisher","first-page":"1315","DOI":"10.1007\/s00467-016-3437-y","article-title":"Effect of mycophenolic acid in experimental, nontransplant glomerular diseases: new mechanisms beyond immune cells","volume":"32","author":"Hackl","year":"2017","journal-title":"Pediatr Nephrol."},{"key":"B152","doi-asserted-by":"publisher","first-page":"210","DOI":"10.1016\/j.kint.2018.08.039","article-title":"Efficacy and safety of mycophenolate mofetil versus levamisole in frequently relapsing nephrotic syndrome: an open-label randomized controlled trial","volume":"95","author":"Sinha","year":"2019","journal-title":"Kidney Int."},{"key":"B153","doi-asserted-by":"publisher","first-page":"1689","DOI":"10.1681\/ASN.2012121200","article-title":"Mycophenolate mofetil versus cyclosporin a in children with frequently relapsing nephrotic syndrome","volume":"24","author":"Gellermann","year":"2013","journal-title":"J Am Soc Nephrol."},{"key":"B154","doi-asserted-by":"publisher","first-page":"772","DOI":"10.1007\/s00467-003-1174-5","article-title":"Novel therapy of focal glomerulosclerosis with mycophenolate and angiotensin blockade","volume":"18","author":"Montan\u00e9","year":"2003","journal-title":"Pediatr Nephrol."},{"key":"B155","doi-asserted-by":"publisher","first-page":"405","DOI":"10.5414\/CNP62405","article-title":"Mycophenolate mofetil in the treatment of focal segmental glomerulosclerosis","volume":"62","author":"Cattran","year":"2004","journal-title":"Clin Nephrol."},{"key":"B156","doi-asserted-by":"publisher","first-page":"286","DOI":"10.3265\/Nefrologia.pre2011.Feb.10870","article-title":"Efficacy and safety of combined cyclosporin A and mycophenolate mofetil therapy in patients with cyclosporin-resistant focal segmental glomerulosclerosis","volume":"31","author":"Segarra Medrano","year":"2011","journal-title":"Nefrologia."},{"key":"B157","doi-asserted-by":"publisher","first-page":"868","DOI":"10.1038\/ki.2011.195","article-title":"Clinical trial of focal segmental glomerulosclerosis in children and young adults","volume":"80","author":"Gipson","year":"2011","journal-title":"Kidney Int."},{"key":"B158","doi-asserted-by":"publisher","first-page":"248","DOI":"10.1016\/j.kint.2017.01.019","article-title":"Mycophenolate mofetil is inferior to tacrolimus in sustaining remission in children with idiopathic steroid-resistant nephrotic syndrome","volume":"92","author":"Sinha","year":"2017","journal-title":"Kidney Int."},{"key":"B159","doi-asserted-by":"publisher","first-page":"1970","DOI":"10.1093\/ndt\/gfr572","article-title":"Sequential maintenance therapy with cyclosporin A and mycophenolate mofetil for sustained remission of childhood steroid-resistant nephrotic syndrome","volume":"27","author":"Gellermann","year":"2012","journal-title":"Nephrol Dial Transplant."},{"key":"B160","doi-asserted-by":"publisher","first-page":"F846","DOI":"10.1152\/ajprenal.00231.2015","article-title":"Melanocortin 1 receptor agonist protects podocytes through catalase and RhoA activation","volume":"310","author":"Elvin","year":"2016","journal-title":"Am J Physiol Renal Physiol."},{"key":"B161","doi-asserted-by":"publisher","first-page":"122","DOI":"10.1038\/nrneph.2011.190","article-title":"The renaissance of corticotropin therapy in proteinuric nephropathies","volume":"8","author":"Gong","year":"2011","journal-title":"Nat Rev Nephrol."},{"key":"B162","doi-asserted-by":"publisher","first-page":"2072","DOI":"10.2215\/CJN.02840313","article-title":"Treatment of idiopathic FSGS with adrenocorticotropic hormone gel","volume":"8","author":"Hogan","year":"2013","journal-title":"Clin J Am Soc Nephrol."},{"key":"B163","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1186\/s12882-016-0241-7","article-title":"Acthar gel in the treatment of nephrotic syndrome: a multicenter retrospective case series","volume":"17","author":"Madan","year":"2016","journal-title":"BMC Nephrol."},{"key":"B164","doi-asserted-by":"publisher","first-page":"387","DOI":"10.1093\/ckj\/sfw045","article-title":"Efficacy and safety of adrenocorticotropic hormone treatment in glomerular diseases: a systematic review and meta-analysis","volume":"9","author":"Kittanamongkolchai","year":"2016","journal-title":"Clin Kidney J."},{"key":"B165","doi-asserted-by":"publisher","first-page":"85ra46","DOI":"10.1126\/scitranslmed.3002231","article-title":"Rituximab targets podocytes in recurrent focal segmental glomerulosclerosis","volume":"3","author":"Fornoni","year":"2011","journal-title":"Sci Transl Med."},{"key":"B166","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1111\/nep.12737","article-title":"Rituximab protects podocytes and exerts anti-proteinuric effects in rat adriamycin-induced nephropathy independent of B-lymphocytes","volume":"22","author":"Takahashi","year":"2017","journal-title":"Nephrology."},{"key":"B167","doi-asserted-by":"publisher","first-page":"e81836","DOI":"10.1172\/jci.insight.81836","article-title":"B cell\u2013derived IL-4 acts on podocytes to induce proteinuria and foot process effacement","volume":"2","author":"Kim","year":"2017","journal-title":"JCI Insight."},{"key":"B168","doi-asserted-by":"publisher","DOI":"10.1007\/s00467-020-04476-9","article-title":"Current understandings in treating children with steroid-resistant nephrotic syndrome","author":"Lee","year":"2020","journal-title":"Pediatr Nephrol"},{"key":"B169","doi-asserted-by":"publisher","first-page":"108","DOI":"10.1159\/000477944","article-title":"High-dose rituximab ineffective for focal segmental glomerulosclerosis: a long-term observation study","volume":"46","author":"Roccatello","year":"2017","journal-title":"Am J Nephrol."},{"key":"B170","doi-asserted-by":"publisher","first-page":"277","DOI":"10.1159\/000368590","article-title":"Rituximab in adult minimal change disease and focal segmental glomerulosclerosis","volume":"128","author":"Kronbichler","year":"2014","journal-title":"Nephron Clin Pract."},{"key":"B171","doi-asserted-by":"publisher","first-page":"1117","DOI":"10.1681\/ASN.2011080775","article-title":"Rituximab in children with resistant idiopathic nephrotic syndrome","volume":"23","author":"Magnasco","year":"2012","journal-title":"J Am Soc Nephrol."},{"key":"B172","doi-asserted-by":"publisher","first-page":"1268","DOI":"10.1056\/NEJMc1308488","article-title":"Ofatumumab for rituximab-resistant nephrotic syndrome","volume":"370","author":"Basu","year":"2014","journal-title":"N Engl J Med."},{"key":"B173","doi-asserted-by":"publisher","first-page":"bcr2015210208","DOI":"10.1136\/bcr-2015-210208","article-title":"Low-dose ofatumumab for rituximab-resistant nephrotic syndrome","volume":"2015","author":"Bonanni","year":"2015","journal-title":"BMJ Case Rep."},{"key":"B174","doi-asserted-by":"publisher","first-page":"997","DOI":"10.1007\/s00467-020-04481-y","article-title":"Low-dose ofatumumab for multidrug-resistant nephrotic syndrome in children: a randomized placebo-controlled trial","volume":"35","author":"Ravani","year":"2020","journal-title":"Pediatr Nephrol."},{"key":"B175","doi-asserted-by":"publisher","first-page":"178","DOI":"10.6002\/ect.MESOT2018.P53","article-title":"Successful treatment with abatacept in recurrent focal segmental glomerulosclerosis after kidney transplant","volume":"17","author":"Shah","year":"2019","journal-title":"Exp Clin Transplant."},{"key":"B176","doi-asserted-by":"publisher","first-page":"469","DOI":"10.1007\/s00467-014-2957-6","article-title":"Case series: CTLA4-IgG1 therapy in minimal change disease and focal segmental glomerulosclerosis","volume":"30","author":"Garin","year":"2015","journal-title":"Pediatr Nephrol."},{"key":"B177","doi-asserted-by":"publisher","first-page":"2520","DOI":"10.1681\/ASN.2015091002","article-title":"B7\u20131 blockade does not improve post\u2013transplant nephrotic syndrome caused by recurrent FSGS","volume":"27","author":"Delville","year":"2016","journal-title":"J Am Soc Nephrol."},{"key":"B178","doi-asserted-by":"publisher","first-page":"513","DOI":"10.1159\/000506277","article-title":"Extracorporeal therapies in the treatment of focal segmental glomerulosclerosis","volume":"49","author":"Raina","year":"2020","journal-title":"Blood Purif."},{"key":"B179","doi-asserted-by":"publisher","first-page":"2938","DOI":"10.1093\/ndt\/gfp278","article-title":"FSGS permeability factor-associated nephrotic syndrome: remission after oral galactose therapy","volume":"24","author":"De Smet","year":"2009","journal-title":"Nephrol Dial Transplant."},{"key":"B180","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s12882-015-0094-5","article-title":"Efficacy of galactose and adalimumab in patients with resistant focal segmental glomerulosclerosis: report of the font clinical trial group","volume":"16","author":"Trachtman","year":"2015","journal-title":"BMC Nephrol."},{"key":"B181","doi-asserted-by":"publisher","first-page":"i14","DOI":"10.1093\/ndt\/gfw324","article-title":"What are we missing in the clinical trials of focal segmental glomerulosclerosis?","volume":"32","author":"Zand","year":"2017","journal-title":"Nephrol Dial Transplant."}],"container-title":["Frontiers in Medicine"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fmed.2020.604961\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,11,29]],"date-time":"2022-11-29T00:05:08Z","timestamp":1669680308000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fmed.2020.604961\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,11,20]]},"references-count":181,"alternative-id":["10.3389\/fmed.2020.604961"],"URL":"https:\/\/doi.org\/10.3389\/fmed.2020.604961","relation":{},"ISSN":["2296-858X"],"issn-type":[{"value":"2296-858X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,11,20]]},"article-number":"604961"}}